header logo image


Page 15«..10..14151617..2030..»

Archive for the ‘Personalized Medicine’ Category

SMART researchers receive Intra-CREATE grant for personalized medicine and cell therapy – MIT News

Friday, October 2nd, 2020

Researchers from Critical Analytics for Manufacturing Personalized-Medicine (CAMP), an interdisciplinary research group at Singapore-MIT Alliance for Research and Technology (SMART), MITs research enterprise in Singapore, have been awarded Intra-CREATE grants from the National Research Foundation (NRF) Singapore to help support research on retinal biometrics for glaucoma progression and neural cell implantation therapy for spinal cord injuries. The grants are part of the NRFs initiative to bring together researchers from Campus for Research Excellence And Technological Enterprise (CREATE) partner institutions, in order to achieve greater impact from collaborative research efforts.

SMART CAMP was formed in 2019 to focus on ways to produce living cells as medicine delivered to humans to treat a range of illnesses and medical conditions, including tissue degenerative diseases, cancer, and autoimmune disorders.

Singapores well-established biopharmaceutical ecosystem brings with it a thriving research ecosystem that is supported by skilled talents and strong manufacturing capabilities. We are excited to collaborate with our partners in Singapore, bringing together an interdisciplinary group of experts from MIT and Singapore, for new research areas at SMART. In addition to our existing research on our three flagship projects, we hope to develop breakthroughs in manufacturing other cell therapy platforms that will enable better medical treatments and outcomes for society, says Krystyn Van Vliet, co-lead principal investigator at SMART CAMP, professor of materials science and engineering, and associate provost at MIT.

Understanding glaucoma progression for better-targeted treatments

Hosted by SMART CAMP, the first research project, Retinal Analytics via Machine learning aiding Physics (RAMP), brings together an interdisciplinary group of ophthalmologists, data scientists, and optical scientists from SMART, Singapore Eye Research Institute (SERI), Agency for Science, Technology and Research (A*STAR), Duke-NUS Medical School, MIT, and National University of Singapore (NUS). The team will seek to establish first principles-founded and statistically confident models of glaucoma progression in patients. Through retinal biomechanics, the models will enable rapid and reliable forecast of the rate and trajectory of glaucoma progression, leading to better-targeted treatments.

Glaucoma, an eye condition often caused by stress-induced damage over time at the optic nerve head, accounts for 5.1 million of the estimated 38 million blind in the world and 40 percent of blindness in Singapore. Currently, health practitioners face challenges forecasting glaucoma progression and its treatment strategies due to the lack of research and technology that accurately establish the relationship between its properties, such as the elasticity of the retina and optic nerve heads, blood flow, intraocular pressure and, ultimately, damage to the optic nerve head.

The research is co-led by George Barbastathis, principal investigator at SMART CAMP and professor of mechanical engineering at MIT, and Aung Tin, executive director at SERI and professor at the Department of Ophthalmology at NUS. The team includes CAMP principal investigators Nicholas Fang, also a professor of mechanical engineering at MIT; Lisa Tucker-Kellogg, assistant professor with the Cancer and Stem Biology program at Duke-NUS; and Hanry Yu, professor of physiology with the Yong Loo Lin School of Medicine, NUS and CAMPs co-lead principal investigator.

We look forward to leveraging the ideas fostered in SMART CAMP to build data analytics and optical imaging capabilities for this pressing medical challenge of glaucoma prediction, says Barbastathis.

Cell transplantation to treat irreparable spinal cord injury

Engineering Scaffold-Mediated Neural Cell Therapy for Spinal Cord Injury Treatment (ScaNCellS), the second research project, gathers an interdisciplinary group of engineers, cell biologists, and clinician scientists from SMART, Nanyang Technological University (NTU), NUS, IMCB A*STAR, A*STAR, French National Centre for Scientific Research (CNRS), the University of Cambridge, and MIT. The team will seek to design a combined scaffold and neural cell implantation therapy for spinal cord injury treatment that is safe, efficacious, and reproducible, paving the way forward for similar neural cell therapies for other neurological disorders. The project, an intersection of engineering and health, will achieve its goals through an enhanced biological understanding of the regeneration process of nerve tissue and optimized engineering methods to prepare cells and biomaterials for treatment.

Spinal cord injury (SCI), affecting between 250,00 and 500,000 people yearly, is expected to incur higher societal costs as compared to other common conditions such as dementia, multiple sclerosis, and cerebral palsy. SCI can lead to temporary or permanent changes in spinal cord function, including numbness or paralysis. Currently, even with the best possible treatment, the injury generally results in some incurable impairment.

The research is co-led by Chew Sing Yian, principal investigator at SMART CAMP and associate professor of the School of Chemical and Biomedical Engineering and Lee Kong Chian School of Medicine at NTU, and Laurent David, professor at University of Lyon (France) and leader of the Polymers for Life Sciences group at CNRS Polymer Engineering Laboratory. The team includes CAMP principal investigators Ai Ye from Singapore University of Technology and Design; Jongyoon Han and Zhao Xuanhe, both professors at MIT; as well as Shi-Yan Ng and Jonathan Loh from Institute of Molecular and Cell Biology, A*STAR.

Chew says, Our earlier SMART and NTU scientific collaborations on progenitor cells in the central nervous system are now being extended to cell therapy translation. This helps us address SCI in a new way, and connect to the methods of quality analysis for cells developed in SMART CAMP.

Cell therapy, one of the fastest-growing areas of research, will provide patients with access to more options that will prevent and treat illnesses, some of which are currently incurable. Glaucoma and spinal cord injuries affect many. Our research will seek to plug current gaps and deliver valuable impact to cell therapy research and medical treatments for both conditions. With a good foundation to work on, we will be able to pave the way for future exciting research for further breakthroughs that will benefit the health-care industry and society, says Hanry Yu, co-lead principal investigator at SMART CAMP, professor of physiology with the Yong Loo Lin School of Medicine, NUS, and group leader of the Institute of Bioengineering and Nanotechnology at A*STAR.

The grants for both projects will commence on Oct. 1, with RAMP expected to run until Sept. 30, 2022, and ScaNCellS expected to run until Sept. 30, 2023.

SMART was. established by the MIT in partnership with the NRF in 2007. SMART is the first entity in the CREATE developed by NRF. SMART serves as an intellectual and innovation hub for research interactions between MIT and Singapore, undertaking cutting-edge research projects in areas of interest to both Singapore and MIT. SMART currently comprises an Innovation Centre and five interdisciplinary research groups (IRGs): Antimicrobial Resistance, CAMP, Disruptive and Sustainable Technologies for Agricultural Precision, Future Urban Mobility, and Low Energy Electronic Systems.

CAMP is a SMART IRG launched in June 2019. It focuses on better ways to produce living cells as medicine, or cellular therapies, to provide more patients access to promising and approved therapies. The investigators at CAMP address two key bottlenecks facing the production of a range of potential cell therapies: critical quality attributes (CQA) and process analytic technologies (PAT). Leveraging deep collaborations within Singapore and MIT in the United States, CAMP invents and demonstrates CQA/PAT capabilities from stem to immune cells. Its work addresses ailments ranging from cancer to tissue degeneration, targeting adherent and suspended cells, with and without genetic engineering.

CAMP is the R&D core of a comprehensive national effort on cell therapy manufacturing in Singapore.

See the original post:
SMART researchers receive Intra-CREATE grant for personalized medicine and cell therapy - MIT News

Read More...

Covid-19 Impact on Personalized Medicine Market Globally Growth Analysis 2020-2026 | Business Opportunities by Evolving Technologies, Global Size…

Friday, October 2nd, 2020

The global Personalized Medicine market focuses on encompassing major statistical evidence for the Personalized Medicine industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Personalized Medicine study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Personalized Medicine industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Personalized Medicine market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Personalized Medicine report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Personalized Medicine market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Personalized Medicine Market report @ https://hongchunresearch.com/request-a-sample/41081

Key players in the global Personalized Medicine market covered in Chapter 4:Amgen Inc.GE HealthcareSiemens Healthcare Diagnostics Inc.Asuragen IncQiagen Inc.Becton Dickinson & Co.Agendia NVPfizer Inc.Bristol-Myers SquibbAbbott

In Chapter 11 and 13.3, on the basis of types, the Personalized Medicine market from 2015 to 2026 is primarily split into:PM DiagnosticsPM TherapeuticsPersonalized Medical CarePersonalized Nutrition & Wellness

In Chapter 12 and 13.4, on the basis of applications, the Personalized Medicine market from 2015 to 2026 covers:Diagnosis and interventionDrug development and usageCancer genomics

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:North America (Covered in Chapter 6 and 13)United StatesCanadaMexicoEurope (Covered in Chapter 7 and 13)GermanyUKFranceItalySpainRussiaOthersAsia-Pacific (Covered in Chapter 8 and 13)ChinaJapanSouth KoreaAustraliaIndiaSoutheast AsiaOthersMiddle East and Africa (Covered in Chapter 9 and 13)Saudi ArabiaUAEEgyptNigeriaSouth AfricaOthersSouth America (Covered in Chapter 10 and 13)BrazilArgentinaColumbiaChileOthers

The Personalized Medicine market study further highlights the segmentation of the Personalized Medicine industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Personalized Medicine report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Personalized Medicine market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Personalized Medicine market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Personalized Medicine industry as it explores the competitive nature of the market complete with a regional analysis.

Brief about Personalized Medicine Market Report with [emailprotected]https://hongchunresearch.com/report/personalized-medicine-market-41081

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Personalized Medicine Market

Chapter Four: Players Profiles

Chapter Five: Global Personalized Medicine Market Analysis by Regions

Chapter Six: North America Personalized Medicine Market Analysis by Countries

Chapter Seven: Europe Personalized Medicine Market Analysis by Countries

Chapter Eight: Asia-Pacific Personalized Medicine Market Analysis by Countries

Chapter Nine: Middle East and Africa Personalized Medicine Market Analysis by Countries

Chapter Ten: South America Personalized Medicine Market Analysis by Countries

Chapter Eleven: Global Personalized Medicine Market Segment by Types

Chapter Twelve: Global Personalized Medicine Market Segment by Applications12.1 Global Personalized Medicine Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Personalized Medicine Sales and Market Share by Applications (2015-2020)12.1.2 Global Personalized Medicine Revenue and Market Share by Applications (2015-2020)12.2 Diagnosis and intervention Sales, Revenue and Growth Rate (2015-2020)12.3 Drug development and usage Sales, Revenue and Growth Rate (2015-2020)12.4 Cancer genomics Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Personalized Medicine Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/41081

List of tablesList of Tables and FiguresTable Global Personalized Medicine Market Size Growth Rate by Type (2020-2026)Figure Global Personalized Medicine Market Share by Type in 2019 & 2026Figure PM Diagnostics FeaturesFigure PM Therapeutics FeaturesFigure Personalized Medical Care FeaturesFigure Personalized Nutrition & Wellness FeaturesTable Global Personalized Medicine Market Size Growth by Application (2020-2026)Figure Global Personalized Medicine Market Share by Application in 2019 & 2026Figure Diagnosis and intervention DescriptionFigure Drug development and usage DescriptionFigure Cancer genomics DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Personalized Medicine Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Personalized Medicine Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of Personalized MedicineFigure Production Process of Personalized MedicineFigure Manufacturing Cost Structure of Personalized MedicineFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Amgen Inc. ProfileTable Amgen Inc. Production, Value, Price, Gross Margin 2015-2020Table GE Healthcare ProfileTable GE Healthcare Production, Value, Price, Gross Margin 2015-2020Table Siemens Healthcare Diagnostics Inc. ProfileTable Siemens Healthcare Diagnostics Inc. Production, Value, Price, Gross Margin 2015-2020Table Asuragen Inc ProfileTable Asuragen Inc Production, Value, Price, Gross Margin 2015-2020Table Qiagen Inc. ProfileTable Qiagen Inc. Production, Value, Price, Gross Margin 2015-2020Table Becton Dickinson & Co. ProfileTable Becton Dickinson & Co. Production, Value, Price, Gross Margin 2015-2020Table Agendia NV ProfileTable Agendia NV Production, Value, Price, Gross Margin 2015-2020Table Pfizer Inc. ProfileTable Pfizer Inc. Production, Value, Price, Gross Margin 2015-2020Table Bristol-Myers Squibb ProfileTable Bristol-Myers Squibb Production, Value, Price, Gross Margin 2015-2020Table Abbott ProfileTable Abbott Production, Value, Price, Gross Margin 2015-2020Figure Global Personalized Medicine Sales and Growth Rate (2015-2020)Figure Global Personalized Medicine Revenue ($) and Growth (2015-2020)Table Global Personalized Medicine Sales by Regions (2015-2020)Table Global Personalized Medicine Sales Market Share by Regions (2015-2020)Table Global Personalized Medicine Revenue ($) by Regions (2015-2020)Table Global Personalized Medicine Revenue Market Share by Regions (2015-2020)Table Global Personalized Medicine Revenue Market Share by Regions in 2015Table Global Personalized Medicine Revenue Market Share by Regions in 2019Figure North America Personalized Medicine Sales and Growth Rate (2015-2020)Figure Europe Personalized Medicine Sales and Growth Rate (2015-2020)Figure Asia-Pacific Personalized Medicine Sales and Growth Rate (2015-2020)Figure Middle East and Africa Personalized Medicine Sales and Growth Rate (2015-2020)Figure South America Personalized Medicine Sales and Growth Rate (2015-2020)Figure North America Personalized Medicine Revenue ($) and Growth (2015-2020)Table North America Personalized Medicine Sales by Countries (2015-2020)Table North America Personalized Medicine Sales Market Share by Countries (2015-2020)Figure North America Personalized Medicine Sales Market Share by Countries in 2015Figure North America Personalized Medicine Sales Market Share by Countries in 2019Table North America Personalized Medicine Revenue ($) by Countries (2015-2020)Table North America Personalized Medicine Revenue Market Share by Countries (2015-2020)Figure North America Personalized Medicine Revenue Market Share by Countries in 2015Figure North America Personalized Medicine Revenue Market Share by Countries in 2019Figure United States Personalized Medicine Sales and Growth Rate (2015-2020)Figure Canada Personalized Medicine Sales and Growth Rate (2015-2020)Figure Mexico Personalized Medicine Sales and Growth (2015-2020)Figure Europe Personalized Medicine Revenue ($) Growth (2015-2020)Table Europe Personalized Medicine Sales by Countries (2015-2020)Table Europe Personalized Medicine Sales Market Share by Countries (2015-2020)Figure Europe Personalized Medicine Sales Market Share by Countries in 2015Figure Europe Personalized Medicine Sales Market Share by Countries in 2019Table Europe Personalized Medicine Revenue ($) by Countries (2015-2020)Table Europe Personalized Medicine Revenue Market Share by Countries (2015-2020)Figure Europe Personalized Medicine Revenue Market Share by Countries in 2015Figure Europe Personalized Medicine Revenue Market Share by Countries in 2019Figure Germany Personalized Medicine Sales and Growth Rate (2015-2020)Figure UK Personalized Medicine Sales and Growth Rate (2015-2020)Figure France Personalized Medicine Sales and Growth Rate (2015-2020)Figure Italy Personalized Medicine Sales and Growth Rate (2015-2020)Figure Spain Personalized Medicine Sales and Growth Rate (2015-2020)Figure Russia Personalized Medicine Sales and Growth Rate (2015-2020)Figure Asia-Pacific Personalized Medicine Revenue ($) and Growth (2015-2020)Table Asia-Pacific Personalized Medicine Sales by Countries (2015-2020)Table Asia-Pacific Personalized Medicine Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Personalized Medicine Sales Market Share by Countries in 2015Figure Asia-Pacific Personalized Medicine Sales Market Share by Countries in 2019Table Asia-Pacific Personalized Medicine Revenue ($) by Countries (2015-2020)Table Asia-Pacific Personalized Medicine Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Personalized Medicine Revenue Market Share by Countries in 2015Figure Asia-Pacific Personalized Medicine Revenue Market Share by Countries in 2019Figure China Personalized Medicine Sales and Growth Rate (2015-2020)Figure Japan Personalized Medicine Sales and Growth Rate (2015-2020)Figure South Korea Personalized Medicine Sales and Growth Rate (2015-2020)Figure Australia Personalized Medicine Sales and Growth Rate (2015-2020)Figure India Personalized Medicine Sales and Growth Rate (2015-2020)Figure Southeast Asia Personalized Medicine Sales and Growth Rate (2015-2020)Figure Middle East and Africa Personalized Medicine Revenue ($) and Growth (2015-2020) continued

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Trending Report URLs:

COVID-19 Outbreak- Global Water Filter Dispensers Market 2020 analysis with Key Players, Applications, Trends and Forecasts by 2026

Global Urology Disposable Market Size, Share, 2020 Movements by Key Findings, Covid-19 Impact Analysis, Progression Status, Revenue Expectation to 2026

Read more:
Covid-19 Impact on Personalized Medicine Market Globally Growth Analysis 2020-2026 | Business Opportunities by Evolving Technologies, Global Size...

Read More...

Big Dreams of Personalized Health – NEO.LIFE

Friday, October 2nd, 2020

When people find out Azizi Seixas studies sleep, they sometimes ask him about their dreams. Thats not really his fieldbut he does have big dreams for his own research. By using technology to combine precision medicine with population-level research, he hopes to erase disparities and bring better health to all.

Growing up in inner-city Kingston, Jamaica, I was the have-nots, Seixas says. He learned early lessons about inequality andbeing raised by seven women in a three-bedroom homeresourcefulness. Today hes carried those lessons to New York Universitys Grossman School of Medicine, where hes an assistant professor of population health and psychiatry. In his lab, Seixas explores why certain groups such as racial and ethnic minorities have higher risks of chronic illnesses, the long-term consequences of those disparities, and how people can change their behavior to improve their health.

Sleep has been a kind of lens through which Seixas looks at these questions. For example, how are disparities in peoples sleep related to heart disease risk and other health effects? And how might doctors tailor sleep advice to individuals, along with their other recommendations?

Thats important because sleep plays an integral role in our health 24/7, not just the hours were in bed. Sleep is not just the act of unconsciousness, Seixas says. Besides keeping our bodies refreshed and running, sleep is important for consolidating things weve learned, and for cleansing our brains of protein gunk thats linked to Alzheimers disease.

Yet not everyone can get as much sleep as they need. He gives the example of a single mother who works two jobs. If he tells her she needs to sleep eight or nine hours a night, Shell look at me and scoff, Seixas says. And they have, to be quite honest.

Seixas imagines working with that single mom to figure out ways to offset her lost sleep using other health recommendations. Maybe dialing up her exercise can lower her risk of certain diseases, even while she continues squeezing in just six hours a night. If exercising more isnt feasible, maybe she can adjust her diet instead. The data to make this happen might come from wearable technologies that track the moms activities and biometrics, as well as artificial intelligence and machine-learning models that predict how changes to her behaviors will affect her health.

Scientists are still learning about the intricate ways our traits, behaviors, and risks may affect each other, so this scenario is still hypothetical. But one goal of Seixass research is to be able to personalize the advice a doctor gives a patient, rather than assuming that the same guidance is right for everybody. Seixas calls his philosophy precision and personalized population health. He thinks general guidelines for the public are important, too. But to fulfill what he calls his sacrosanct role in public health, he wants to find precisely the right way to help that single mother, or anyone else, stay healthy.

How is their nightly sleep related to their daily steps?

Some of his research hints that it might be possible. In a 2018 paper, he and his colleagues used machine learning to analyze survey data from more than 280,000 people about whether theyd had a stroke, as well as their age, sex, nightly sleep, and physical activity. The analysis showed which combinations of factors put people at higher or lower risk of strokes. In a similar 2017 paper, Seixas and others calculated which combinations of activity, sleep, stress, and body mass index were linked to the lowest diabetes risk in Black and white Americans.

The more health data he can include from a diverse range of people, the better the recommendations that might emerge from it. Among many other projects to help improve these datasets, Seixas is soon launching a study with funding from Merck that will focus on people with hypertension and diabetes. Seixas and his team created an app that will give participants higher-level analyses from the Fitbits or other health trackers they already use. For example, how is their nightly sleep related to their daily steps? The app will also automatically gather health-related news and articles that might interest the user. And, critically, it will tell users about clinical trials they can enroll in. We want to appeal to the greater good of individuals, Seixas says, tapping into peoples drive for altruism and volunteering to fight chronic health conditions.

Encouraging more people to enroll in clinical trialswhich include trials of behavioral changes, not just tests of new drugscould help researchers get better data on underrepresented groups. Seixas hopes it could also help the public to see science in a positive light. Especially now, he says, where you have political figures questioning whether or not science should be the bright force that it has always been.

Seixass ideas are especially timely during COVID-19, says Girardin Jean-Louis, a professor of population health and psychiatry at NYU Langone Health, who is Seixass mentor. During the pandemic, vulnerable communities are having an especially hard time accessing healthcare. His research is poised to address how various health issues plaguing underserved communities can be addressed adequately, Jean-Louis says.

Seixas hopes the questions he and his research group at NYU are asking will someday help to transform healthcare. We have very ambitious dreams and goals, he says.

Go here to read the rest:
Big Dreams of Personalized Health - NEO.LIFE

Read More...

Innovative Gx Laboratories Announces the Grand Opening of Its Molecular Diagnostic Laboratory in Texas – PRNewswire

Friday, October 2nd, 2020

SAN ANTONIO, Oct. 1, 2020 /PRNewswire/ --Innovative Gx Laboratories, a Texas-based molecular diagnostic company, is announcing the grand opening of its central testing laboratory in San Antonio, Texas, on Oct. 1, 2020. Innovative Gx specializes in molecular diagnosis using real-time RT PCR and DNA sequencing in many medical areas. The company is a leader in personalized medical solutions such as Respiratory Pathogens, Infectious Disease, COVID-19, and DNA-based Pharmacogenetics (PGX) testing services delivering genetic-based treatment of patient care.

Innovative Gx Laboratories was founded in 2019by a team of careermedical diagnostic scientists with a combined 30+ years of experience. Its scientific team is dedicated to providing the highest-quality clinical testing services to help people reach the best health through personalized medicine. The company offers high-accuracy testing, ship-to-home (reviewed by an independent physician) or B2B solutions, offering diagnostic kitsand rapid results (often delivered in as little as less than 24 hours) for its physicians, hospitals, and clinics it serves nationwide.

Innovative Gx Laboratories provides one of the most comprehensive molecular testing options for physicians to help them accurately diagnose and treat many diseases through its targeted pharmacogenomic (PGX) panels. At present, Innovative Gx PGX panels include medications commonly prescribed to treat cardiovascular disease, mental health, infectious disease, cancer, and adverse drug interactions, and examineover 62 genes and 200 gene variants.

Innovative GX Laboratories also specializes in molecular testing of infectious disease, identification of a large range of respiratory pathogens, and RT PCR-based COVID testing. The Innovative Gx RT PCR COVID-19 Test is considered the "gold standard" in COVID screening and has received FDA authorization for emergency use. The test's level of accuracy is much higher than antigen and antibody testing and attains 99% determination of virus present.

"Our team of scientists and physicians at Innovative Gx Laboratories work diligently to offer the most comprehensive testing panels for our hospitals, physicians, and patients," said Enrique Perez-Paris, one of the co-founders of the company. He added, "Innovative Gx is much more than a business venture. It is my legacy, allowing the team at IG, to help others by providing precise health information in an accurate and timely manner."

For more information about Innovative Gx Laboratories and details of its services, please visit or contact the company at:

Innovative Gx Laboratories5410 Fredericksburg Road, Suite A304, San Antonio, Texas 78229(866) 3PCR-DNA[emailprotected] https://innovativegx.com

Related Files

InnovativeGx Laboratories Grand Opening Press Release.docx

Related Images

logo.jpg Logo

SOURCE Innovative Gx Laboratories

Innovative GX

Read more from the original source:
Innovative Gx Laboratories Announces the Grand Opening of Its Molecular Diagnostic Laboratory in Texas - PRNewswire

Read More...

Why it’s so hard to guess who’s going to get a Nobel Prize – The Albany Herald

Friday, October 2nd, 2020

The Nobel Prizes for Physics, Chemistry and Medicine are the acme of scientific achievement -- honoring great minds and life-changing discoveries. But predicting who will be summoned to Stockholm and win the accolades, which are announced next week, is easy to get wrong.

That doesn't mean that people don't try.

Some look at which scientists have won so-called predictor prizes like the Lasker Awards for medical science, others analyze the fields of study favored by the Nobel Committee and tally how many years pass before a specific field is honored.

Complicating matters is that the Nobel selection committee, according to the rules laid down by Swedish industrialist Alfred Nobel in 1895, can only honor up to three people -- something that is getting harder given the collaborative nature of much scientific research.

Pandemic medicine

Unlike the peace prize, which often raises some eyebrows, the science prizes tend to honor achievements that have withstood the test of time -- last year's prize in chemistry recognized research in the development of lithium batteries from the 1980s that included honoring the oldest winner ever. The distinctions in science are thus less likely to generate controversy.

This means that it's highly unlikely that the fast-moving scientific research into Covid-19 will be featured, although many think that a drug to treat the disease or vaccine to stop its spread is a potential future winner.

That said, Gilbert Thompson, professor emeritus of clinical lipidology at Imperial College London, thinks that the committee could honor two scientists, Max Cooper and Jacques Miller, whose discovery about the organization and function of the human immune system, in particular B cells and T cells, is underpinning vaccine research.

Eman Ghanem, membership director at Sigma Xi, a global association of around 30,000 scientists that includes some 200 Nobel prize winners, is hopeful that there will be a female Nobel Laureate in science after an all-male lineup in 2019.

Success! An email has been sent to with a link to confirm list signup.

Error! There was an error processing your request.

Citations

David Pendlebury, a senior citation analyst at Clarivate Analytics, since 2002 has made 54 correct predictions (though not usually in the right year) by analyzing how often a scientist's key papers are cited by peers. Out of some 50 million scientific papers indexed since 1970, only 5,700 (or 0.01%) have been cited 2,000 or more times, and this is the pool from which his prediction are drawn.

"We're not saying that these particular people are going to win in a particular year," Pendlebury said. "We're saying these people are Nobel class and are likely to win a Nobel prize at some point.

For the physics prize, one of three contending groups Pendlebury lists is Carlos Frenk of Durham University, Julio Navarro of University of Victoria in Canada and Simon White, former director at the Max Planck Institute for Astrophysics, for their work into galaxy formation, cosmic structure and dark matter. However, Pendlebury said a win this year is unlikely because last year's physics prize for the first discovery of planets outside our solar system, led by Princeton astrophysicist James Peebles, was from the same field.

"It's highly cited, essential work, but I think it will probably be a few years till they return to a prize in cosmology," he said. "Though they could prove me wrong."

Conservative choices

The CRISPR gene-editing technology, is often mentioned as a candidate for the chemistry prize, but Pendlebury said it was a potential minefield for a Nobel Committee that likes to play it safe.

While worthy, he said several groups of scientists have been collaborating on gene editing, making it hard to narrow it down to three names. Moreover, the technology had until recently been tied up in patent wrangles. (And that's notwithstanding the ethical concerns that have dogged the technology in the wake of Chinese scientist He Jiankui, who was jailed for creating the world's first gene-edited babies.)

"I think they are making conservative choices on the significance of the science," he said.

For medicine, Pendlebury's picks include Yusuke Nakamura, a Japanese geneticist, whose contributions in pioneering whole genome sequencing gave birth to the field of personalized medicine that has revolutionized cancer treatment; and Lebanese scientist Huda Y. Zoghbi, for her work on neurological disorders including the genetic origins of Rett syndrome, a rare genetic neurological disorder that occurs primarily in girls. She was the 2017 winner of a $3 million Breakthrough Prize in Life Sciences -- founded by Sergey Brin, Priscilla Chan and Mark Zuckerberg.

"She's a very good example of someone who's likely to get Nobel recognition because of the awards she's been getting," Pendlebury said. "It's not just the accumulation of citations. Receiving these top prizes, which are chosen and selected by your peers, you get a stronger and stronger signal of how important this work has been."

Read the original here:
Why it's so hard to guess who's going to get a Nobel Prize - The Albany Herald

Read More...

Principal Investigator job with HAMAD BIN KHALIFA UNIVERSITY | 227841 – Times Higher Education (THE)

Friday, October 2nd, 2020

Hamad Bin Khalifa University (HBKU), a member of Qatar Foundation for Education, Science, and Community Development (QF), was founded in 2010 to continue fulfilling QFs vision of unlocking human potential. HBKU is a homegrown research and graduate studies University that acts as a catalyst for positive transformation in Qatar and the region while having a global impact.

About Qatar Biomedical Research Institute:

Qatar Biomedical Research Institute (QBRI), part of Hamad Bin Khalifa University (HBKU), is a national center of excellence in biomedical research. It aims to transform healthcare through harnessing and converting the latest advances in science, medicine and technology into novel discoveries that will lead to more effective treatments and preventive strategies for human diseases such as: diabetes, cancer and neurological disorders. The institute strives toward the development of novel diagnostic and therapeutic strategies to facilitate early diagnosis, treatment and management of these devastating diseases with the purpose of improving personalized medicine and healthcare. QBRI has recently occupied state-of-the-art life sciences laboratories in a newly established research campus.

Job Purpose:

To lead and develop a team of scientists and researchers leading to QBRI's growth and address developmental healthcare needs of Qatar. Conceive and establish competitive research programs including conducting translational research.

Key Result Areas:

Operating Environment, Framework & Boundaries:

Communications and Working Relationships:

Problem Solving & Complexity:

Decision-Making Authority & Responsibility:

Minimum Knowledge, Skills & Experience:

Additional Requirements

How to apply

Please submit your completed application (CV, cover letter and the names of three references with their full contact information) via the following link: Click here to apply

Hamad Bin Khalifa University, being an equal opportunity educator and employer, is committed to maintaining culturally and academically diverse staff of the highest caliber.

Read more:
Principal Investigator job with HAMAD BIN KHALIFA UNIVERSITY | 227841 - Times Higher Education (THE)

Read More...

Asia Pacific Stepper Motor Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Type, Technology, and End user, and Country -…

Friday, October 2nd, 2020

New York, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Asia Pacific Stepper Motor Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type, Technology, and End user, and Country" - https://www.reportlinker.com/p05974341/?utm_source=GNW Additionally, the 3D printing technology offers a huge opportunity for medical companies in empowering a rapid production of medical implants, as well as transforming the way of planning procedures by surgeons and doctors.

Moreover, 3D-printed anatomical models are becoming essential and useful tools in the current practice of precision medicine as well as for personalized treatments.Also, additive manufacturing for the healthcare industry is still an ongoing process; however, it has already been applied in several different techniques in the medical field.

These developments in the medical field have increased the applications of stepper motors, thus, supporting the growth of stepper motor market.Based on type, the stepper motor market is further segmented into integrated lead screw stepper motor, rotary stepper motor, and fully-enclosed stepper drives.The rotary stepper motor segment held the largest share of the stepper motor market in 2019.

Rotary stepper motors are brushless and synchronous electric motors, which split a full rotation of the motor into number of equal steps.They act as synchronous AC motors comprising several poles, which are mounted on both rotor and stator.

These motors are used in a wide range of systems in an industrial setup, such as multi-axis machines, CNC machines, rotation stages, high-speed pick and place equipment, constantly driving linear actuators, linear stages, lead screws or ball screws, and mirror mounts.Several governments in APAC are taking possible steps to reduce the effects of COVID19 by announcing lockdown, which is impacting the revenue generated by the market.Although, China is one of the leading manufacturing sectors in the region, it is the most affected country in APAC due to COVID-19.

However, China has been able to minimize the spread of COVID-19, and the industries are back to normal run.Several players in the country have witnessed decline in market trends over the past three months.

Further, India, Japan, South Korea, and Taiwan are still combating the virus, and are exercising lockdown, which is hampering the growth of stepper motor market.The overall APAC stepper motor market size has been derived using primary and secondary sources.To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the stepper motor market.

The process also serves the purpose of obtaining an overview and forecast for the APAC stepper motor market with respect to all the segments pertaining to the region.Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic.

The participants who take part in such a process include industry experts such as VPs, business development managers, stepper motor market intelligence managers, and national sales managers along with external consultants such as valuation experts, research analysts, and key opinion leaders specializing in the APAC stepper motor market. FAULHABER Group; Oriental Motor USA Corp.; SANYO DENKI CO., LTD; Nidec Corporation; Nippon Pulse Motor Co. Ltd.; ABB Ltd.; Schneider Electric SE; National Instruments Corporation; and Delta Electronic are among a few players operating in the APAC stepper motor market.Read the full report: https://www.reportlinker.com/p05974341/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Link:
Asia Pacific Stepper Motor Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type, Technology, and End user, and Country -...

Read More...

Whole Exome Sequencing – Global Market Trajectory & Analytics to 2027 with Short-Term COVID-19 Impact Analysis 2020-2021 – ResearchAndMarkets.com…

Friday, October 2nd, 2020

TipRanks

President Trumps announcement that he has tested positive for the corona virus has grabbed headlines, but the dog that didnt bark presents a more interesting point. Wall Street isnt so worried about corona virus anymore; the perception is, that the virus will fade away or a vaccine will be developed, but in either case, the economy will improve.According to an RBC survey of portfolio managers, however, the coming November election presents a clear risk to the markets. A large majority of investors surveyed, 76%, worry that the election will be contested, resulting in weeks possibly months on uncertainty. And uncertainty is bad for the markets.Recent events, and some not-to-distant history, bear them out. For the history, we must only look back to 2000, when it took until December 12, and an appeal to the Supreme Court, to decide the results of the Florida recount. The S&P 500 slipped 5% during those weeks and that was uncertainty caused by one state, recounting a limited number of votes. The point here is not that this election will be fraudulent or illegitimate. Rather, like Caesars wife, the election should be above the perception of impropriety and this year, that bar may be too high. And then the challenges will begin. In the RBC survey, 83% of portfolio managers believed that such challenges, contesting the election results (from either direction) would be a net negative for the stock market. And only a small minority, 14%, believe that the final results will be known when the polls close on Election Day, November 3.And this is what brings us to dividend stocks today. When investors get nervous, they go looking for a way to protect their portfolios and dividends, making the promise of a steady income stream, may be just the answer skittish shareholders are looking for.Analysts from research firm Compass Point agree. They have picked three stocks whose dividends are yielding 7% or more. Weve pulled up the TipRanks data to find out what else makes these compelling buys in turbulent times.Saratoga Investment Corporation (SAR)Well start with Saratoga Investment Corporation, a mid-market investment management company that specializes in debt, appreciation, and equity investments. Saratoga has over $480 million in assets under management, and its portfolio includes home security, industry, software, and waste disposal. The variety, and the stocks chosen, are designed to give the company a resilient income stream.That doesnt mean that Saratoga has been able to dodge the corona bullet. The company saw revenues turn negative in Q2, and has seen EPS slip from 61 cents in the first quarter to 51 cents in the second. As a result, Saratoga announced that it was deferring its fiscal Q4 dividend, as a cash-saving measure during the pandemic crisis.Saratoga, in July, declared its fiscal Q1 dividend for 40 cents per common share and paid it out in August. There are grounds for confidence. The company has $9 million in committed, but undrawn, lending available, along with $155 million in available credit facilities, a new $43.1 million baby bond issue, and $282 million equity all set against just $60 million in long-term debt.As for the restored dividend, while down 28% from the companys last dividend payment, the new distribution reflects Saratogas liquidity position. The current payment annualizes to $1.60, and gives a yield of 9.2%, or more than 4.5x the average yield found among S&P-listed companies.Covering the stock for Compass Point, analyst Casey Alexander writes of the new dividend, [With] the dividend now officially reset at $0.40 per quarter, it's time to make lemonade from the lemons investors were handed In our view, while we may not be done with credit issues, SAR has set the dividend at a level that allows the BDC to return to the pattern of QoQ dividend increases as the current earnings power of the BDC well exceeds the level of the new dividend.Taking everything into account, Alexander rates SAR stock a Buy, and gives it a $19.75 price target implying an upside of 16% for the coming year. (To watch Alexanders track record, click here)Overall, Saratoga gets a unanimous Strong Buy rating from the analyst consensus, based on 3 recent positive reviews. The shares are selling for $17.02 and have an average price target of $22.58, slightly more bullish than Alexanders and suggesting a one-year upside of ~33%. (See SAR stock analysis on TipRanks)Solar Capital, Ltd. (SLRC)The next stock on our list, Solar Capital, is an investor in senior secured loans and subordinated debt, with an investment portfolio of middle-market companies. The company puts capital into investment-grade loan instruments, making additional financing available to its customer base. Solar Capital has a portfolio worth $1.4 billion invested in 183 companies across 80 business sectors.Solar Capital has been able to keep earnings positive during the corona half, despite a sharp fall in the bottom line for Q1 and Q2. In a bright spot, revenues, which turned negative in Q1, were back to positive in Q2, and projections for Q3 earnings show that the fall-off is either slowing or stopping we will find out which in the Q3 report on November 5.Through all of this uncertainty, Solar Capital has kept up its stable dividend. The company has a 7-year history of reliable dividend payments, and the current quarterly dividend of 41 cents has been paid out consistently for the last 11 quarters. At an annualized payment of $1.64, the dividend currently yields 10.5%. In a time of near-zero official interest rate policy, this gives SLRC an enviable return.Compass Point's Casey Alexander, who also covers SAR, points out that SLRCs dividend is the main attraction for investors and that management has cultivated it for just that purpose. Management stated their intention to continue to pay the $0.41 per share dividend because they believe there is visibility to dividend coverage as they begin to originate new assets at higher spreads. This is the environment that SLRC has been waiting for, and has been the principal reason for maintaining an under-leveraged posture for the last several years, Alexander noted.With dividend coverage visible ahead, Alexander gives SLRC a Buy rating. His price target, at $17.75, indicates confidence in a 12% upside potential.This is another stock with a unanimous Strong Buy consensus rating. SLRC is sitting pretty with 5 positive reviews on record. The average price target is $18.20, representing a ~15% upside from the current share price of $15.86. (See SLRC stock analysis on TipRanks)First Hawaiian (FHB)Our last stock today, First Hawaiian, is the holding company owning the First Hawaiian Bank. First Hawaiian offers the usual array of banking services to retail and commercial customers, with 53 branches throughout the Hawaiian Islands along with three others in Guam and two on Saipan. Banking services include loans, deposit accounts, credit and debit cards, mortgages, insurance, and retirement plans.The recently ended second-quarter showed some mixed results. Top line revenues showed a sequential slip, from $164 million to $152 million, but that was mild compared to the 46% drop in earnings. EPS for Q2 came in at 16 cents, on $20 million in net income. Bright spots for the quarter were total loans, which grew 3% to $383 million, and deposit balances, which increased 13% sequentially to reach $2.3 billion. The banks total assets at the end of 2Q20 were $23 billion, up 10% from the end of the first quarter.That is the background behind managements July dividend declaration. The company Board approved a 26-cent regular quarterly dividend, which was paid out in early September. At $1.04 annualized, this dividend yields 7.2%, putting it well above the average yield and far higher than the current yield on Treasury bonds. FHB has a 4-year history of reliable dividend payments, and the current declaration marks the seventh quarter in a row at the current level.Compass Point analyst Laurie Havener Hunsicker believes a macro look at FHB justifies a bullish stance. FHB was a clear outperformer on credit during the last crisis. While past results do not dictate future performance, we are impressed with the FHB management team and their credit culture; further, we believe that FHB is well-postured to again outperform on credit during the COVID-19 crisis, the analyst noted.In line with her comments, Hunsicker rates FHB a Buy and sets a $21 price target that suggests room for a robust share appreciation of 46% over the next year. (To watch Hunsickers track record, click here)However, Wall Street is unsure on FHB, and the analysts are evenly divided, with recent reviews coming in at 1 Buy, 1 Hold, and 1 Sell for an analyst consensus rating of Hold. FHB shares are selling for $14.42 and have an average price target of $16.67, making the upside potential 15%. (See First Hawaiians stock analysis at TipRanks)To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Read more from the original source:
Whole Exome Sequencing - Global Market Trajectory & Analytics to 2027 with Short-Term COVID-19 Impact Analysis 2020-2021 - ResearchAndMarkets.com...

Read More...

The North America neurological biomarkers market is expected to reach US$ 2,618.68 Mn in 2027 from US$ 7,056.76 Mn in 2019 – PRNewswire

Friday, October 2nd, 2020

NEW YORK, Sept. 30, 2020 /PRNewswire/ --The North America neurological biomarkers market is expected to reach US$ 2,618.68 Mn in 2027 from US$ 7,056.76 Mn in 2019. The market is estimated to grow with a CAGR of 13.4% from 2020-2027.

Read the full report: https://www.reportlinker.com/p05974400/?utm_source=PRN

Factors such as growing prevalence of neurological disorders and increasing focus toward research in neurological biomarker are expected to fuel the growth of the market.However, the limitation of neurological biomarkers is a major factor hindering the market growth.

In addition, increasing awareness toward benefits of early diagnosis is expected to provide growth opportunities to the market players for developing new biomarkers whereas, the inclination toward personalized/precision medicine is expected to be a prevalent trend in the market.Biomarkers are the molecules that indicate about the presence of a disease.The biomarkers of the neurological diseases were not that accessible in earlier days, however the advancements in the technology have enabled to track the health condition of the brain by measuring the biomarkers.

This helps in the earlier detection of a disease, less invasive diagnostics and enables faster drug development and is expected to be the effective treatment.Rapid developments in healthcare and drug discovery sector are leading to the introduction of new therapeutic solutions for the treatment of neurological diseases. Authorities such as World Health Organization, National Institute of Neurological Disorders and Stroke, and National Institutes of Health are taking constructive steps to encourage the research activities and find a remedy for neurological disease treatment.A biomarker is an indicator of normal biological processes, pathogenic processes, or evaluating a therapeutic intervention. Thus, the discovery of biomarker is an active research area, where a few biomarkers have been sufficiently studied and validated for its use in clinical practice and clinical trials.The National Institute of Neurological Disorders and Stroke (NINDS) biomarker program is focused on enhancing the quality and efficiency of neurotherapeutic clinical research and supports the biomarker validation.The program promotes rigorous biomarker identification and validation by providing funds for the research activities.

Similarly, Parkinson's disease Biomarkers Program (PDBP) was initiated to support new and existing research promoting the discovery of biomarker for Parkinson's disease. Thus, increasing number of research studies conducted in the North American region focusing toward advancements in neurological biomarker are expected to augment the growth of the market over the forecast period.

Research institutes, pharmaceutical, and biotech companies are engaged in collaborative work to address the COVID-19 outbreak.This has eventually shifted their focus from development of new neurological biomarkers to vaccine development for COVID-19.

Moreover, diversion of resources from neurological biomarkers development to coronavirus treatment is likely to hamper overall productivity of the drug development during the forecast period. Furthermore, supplies for biotechnology procedures and procurement are also badly affected by the outbreak of COVID-19 in North America.In 2019, the genomic biomarkers segment held the largest share of the market and is expected to grow at the fastest CAGR during the forecast period.This segment is likely to witness a lucrative growth owing to increasing awareness among consumers regarding benefits of genetic medicines as well as technological advancements in the field of neurological biomarkers.

In addition, the trend shift towards adoption of gene counseling and genetic analysis for diagnostic purposes is also likely to augment the growth of the segment. The genetic biomarkers are significant modalities that directs towards a more personalized approach of predispositions and medical analysis.Some of the significant secondary sources for neurological biomarkers market included in the report are the World Health Organization (WHO), Food and Drug Administration (FDA),National Institute of Neurological Disorders and Stroke (NINDS),Centers for Disease Control and Prevention (CDC),and others.

Read the full report: https://www.reportlinker.com/p05974400/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

View original post here:
The North America neurological biomarkers market is expected to reach US$ 2,618.68 Mn in 2027 from US$ 7,056.76 Mn in 2019 - PRNewswire

Read More...

Astonishing growth in Precision Medicine Software Market is expected to grow at CAGR 12.3% from 2019 to 2027 – Crypto Daily

Friday, October 2nd, 2020

Some of the prominent players operating in the precision medicine software market include 2bPrecise, Syapse, Inc., IBM Corporation

Precision medicine is a prototype in healthcare which provides the customization of healthcare with medical decisions, practices, treatments, and products for patients in person. It states about right therapeutic approach for the right patient at the right time. The use of precision medicine is to identify which treatment approach is effective for patients on the basis of genetic, environment, and lifestyle factors. Precision medicine software allows the healthcare professionals (HCPs) to provide personalized treatment plans to patients based on their genetic content. It gives a wide range of applications in both the clinical and diagnostic areas and it combines genetic and clinical data to cater targeted patient care, which is increasing the demand of precision medicine software market.

Request a [emailprotected] https://www.absolutemarketsinsights.com/request_sample.php?id=349

The global precision medicine software market is experiencing lucrative growth owing to the increase in the number of patients suffering from chronic diseases such as cancer, heart diseases, and diabetes. For instance, as per the data presented by International Agency for Research on Cancer (IARC), in 2018, the cancer burden was 18.1 million new cases and 9.6 million deaths across the world. One in five men and one in six women around the globe develop cancer during their lifetime, and one in eight men and one in 11 women die from the disease.

Koninklijke Philips N.V. (Philips Healthcare), a multinational electronics company focusing on healthcare, offers precision medicine platform, namely, IntelliSpace. It enables end-to-end oncology care or cancer management. The platform unifies and streamlines oncology care throughout the patient journey from molecular diagnostics to therapy recommendations. IntelliSpace, a precision medicine oncology solution integrates information over different clinical domains such as pathology, electronic health record (EHR) systems, radiology, and genomics. It consolidates all key patient and medical data in one location to represent a clear, comprehensible view of patient status in its disease and enable data driven clinical decision support, which in turn is propelling the precision medicine software market.

Enquiry Before [emailprotected] https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=349

Precision medicine with the integration of artificial intelligence (AI) will go to the next level with more accuracy and prediction of outcome for patients. Its major benefit for precision medicine is that it predicts outcomes as well as enables healthcare professionals to predict patients probability of having diseases in the future, thus driving the demand of precision medicine software market. Oracle, an American multinational computer technology corporation offers precision medicine software that enables researchers, clinicians, and molecular pathologists to work together. The software addresses data aggregation, normalization and workflow issues, knowledge exchange which restricts timely creation of patient molecular profiles and it also enables spectrum testing from gene panels through whole genome sequencing, and integration with electronic health record systems for seamless clinical workflow.

The detailed research study provides qualitative and quantitative analysis of the global precision medicine software market. The precision medicine software market has been analyzed from demand as well as supply side. The demand side analysis covers market revenue across regions and further across all the major countries. The supply side analysis covers the major market players and their regional and global presence and strategies. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

Request for [emailprotected] https://www.absolutemarketsinsights.com/request_for_customization.php?id=349

Key Findings of the Report:

Global Precision Medicine Software Market

Get Full Information of this premium [emailprotected] https://www.absolutemarketsinsights.com/reports/Precision-Medicine-Software-Market-2019-2027-349

About Us:

Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization.

From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:

Company: Absolute Markets Insights

Email id: [emailprotected]

Phone: +91-740-024-2424

Contact Name: Shreyas Tanna

The Work Lab,

Model Colony, Shivajinagar, Pune, MH, 411016

Website: https://www.absolutemarketsinsights.com/

Continue reading here:
Astonishing growth in Precision Medicine Software Market is expected to grow at CAGR 12.3% from 2019 to 2027 - Crypto Daily

Read More...

Industry VoicesAI doesn’t have to replace doctors to produce better health outcomes – FierceHealthcare

Friday, October 2nd, 2020

Americans encounter some form of artificial intelligence and machine learning technologies in nearly every aspect of daily life: We accept Netflixs recommendations on what movie we should stream next, enjoy Spotifys curated playlists and take a detour when Waze tells us we can shave eight minutes off of our commute.

And it turns out that were fairly comfortable with this new normal: A survey released last year by Innovative Technology Solutions found that, on a scale of 1 to 10, Americans give their GPS systems an 8.1 trust and satisfaction score, followed closely by a 7.5 for TV and movie streaming services.

But when it comes to higher stakes, were not so trusting. When asked about whether they trust an AI doctor diagnosing or treating a medical issue, respondents scored it just a 5.4.

CMS Doubles Down on CAHPS and Raises the Bar on Member Experience

A new CMS final rule will double the impact of CAHPS and member experience on a Medicare plans overall Star Rating. Learn more and discover how to exceed member expectations and improve Star Ratings in this new whitepaper.

Overall skepticism about medical AI and ML is nothing new. In 2012, we were told that IBMs AI-powered Watson was being trained to recommend treatments for cancer patients. There were claims that the advanced technology could make medicine personalized and tailored to millions of people living with cancer. But in 2018, reports surfaced that indicated the research and technology had fallen short of expectations, leaving users to speculate the accuracy of Watsons predictive analytics.

RELATED:Investors poured $4B into healthcare AI startups in 2019

Patients have been reluctant to trust medical AI and ML out of fear that the technology would not offer a unique or personalized recommendation based on individual needs. A piece in Harvard Business Review in 2019 referenced a survey in which 200 business students were asked to take a free health assessment to perform a diagnosis40% of students signed up for the assessment when told their doctor would perform the diagnosis, while only 26% signed up when told a computer would perform the diagnosis.

These concerns are not without basis. Many of the AI and ML approaches that are being used in healthcare todaydue to simplicity and ease of implementationstrive for performance at the population-level by fitting to the characteristics most common among patients. They look to do well in the general case, failing to serve large groups of patients and individuals with unique health needs. However, this limitation of how AI and ML is being applied is not a limitation of the technology.

If anything, what makes AI and ML exceptionalif done rightis its ability to process huge sets of data comprising a diversity of patients, providers, diseases and outcomes and model the fine-grained trends that could potentially have a lasting impact on a patients diagnosis or treatment options. This ability to use data in the large for representative populations and to obtain inferences in the small for individual-level decision support is the promise of AI and ML. The whole process might sound impersonal or cookie-cutter, but the reality is that the advancements in precision medicine and delivery will make care decisions more data-driven and thus more exact.

Consider a patient choosing a specialist. Its anything but data-driven: Theyll search for a provider in-network or maybe one that is conveniently located, without understanding potential health outcomes as a result of their choice. The issue is that patients lack the proper data and information they need to make these informed choices.

RELATED:The unexpected ways AI is impacting the delivery of care, including for COVID-19

Thats where machine intelligence comes into playan AI/ML model that is able to accurately predict the right treatment, at the right time, by the right provider for a patient, which could drastically help reduce the rate of hospitalizations and emergency room visits.

As an example, research published last month in AJMC looked at claims data from 2 million Medicare beneficiaries between 2017 and 2019 to evaluate the utility of ML in the management of severe respiratory infections in community and post-acute settings. The researchers found that machine intelligence for precision navigation could be used to mitigate infection rates in the post-acute care setting.

Specifically, at-risk individuals who received care at skilled nursing facilities (SNFs) that the technology predicted would be the best choice for them had a relative reduction of 37% for emergent care and 36% for inpatient hospitalizations due to respiratory infections compared to those who received care at non-recommended SNFs.

This advanced technology has the ability to comb through and analyze an individuals treatment needs and medical history so that the most accurate recommendations can be made based on that individuals personalized needs and the doctors or facilities available to them. In turn, matching a patient to the optimal provider has the ability to drastically improve health outcomes while also lowering the cost of care.

We now have the technology where we can use machine intelligence to optimize some of the most important decisions in healthcare. The data show results we can trust.

Zeeshan Syed is the CEO and Zahoor Elahi is the COO of Health at Scale.

Read more from the original source:
Industry VoicesAI doesn't have to replace doctors to produce better health outcomes - FierceHealthcare

Read More...

$1.9 Billion Mice Model Market by Mice Type, Technology, Application, Service, Care Products – Global Forecast to 2025 – ResearchAndMarkets.com -…

Friday, October 2nd, 2020

DUBLIN--(BUSINESS WIRE)--The "Global Mice Model Market by Mice Type (Inbred, Knockout), Technology (CRISPR, TALEN, ZFN), Application (Oncology, Diabetes, Immunology), Service (Breeding, Cryopreservation, Genetic Testing), Care Products (Cages, Bedding, Feed), and Region - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global mice model market size is projected to reach USD 1.9 billion by 2025 from USD 1.4 billion in 2020, at a CAGR of 6.4% during the forecast period.

The growth of this market is driven mainly by ongoing innovations in mice models, growing demand for personalized medicine, continuous support in the form of grants and investments, growth in the number of pharmaceutical R&D activities, and increasing focus of associations on the development of embryonic stem cells as well as knockout and mutant mice. Moreover, the popularity of humanized mice models and emerging technologies such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) will present lucrative opportunities for the market in the coming years.

By mice type, the genetically engineered mice accounted for the fastest-growing segment of the mice model market

Genetically engineered mice segment is anticipated to be the fastest-growing due to the widespread use of these mice in diverse research areas, the emerging CRISPR technology, increasing focus on personalized medicine with the continuous introduction of new models

By service, the breeding segment accounted for the largest share of the mice model market

The breeding segment is expected to account for the largest market share in 2020, with the highest growth rate as well. This can primarily be attributed to the increasing demand for mice models for drug discovery and development and the subsequent increase in the demand for personalized medicines.

Oncology segment expected to grow at the fastest growth rate during the forecast period

Based on application, the mice model market has been segmented into oncology studies, immunology and inflammation studies, endocrine metabolic studies, cardiovascular studies, central nervous system studies (CNS), genetic studies, infectious disease studies, and other disease studies. The endocrine disease studies segment is further segmented into diabetes and other endocrine metabolic disease. The oncology segment is expected to account for the largest market share in 2020, with the highest growth rate as well. This can primarily be attributed to the increasing number of patients who have cancer and the subsequent increase in the demand for cancer therapies.

By technology type, CRISPR/Cas9 accounted for the largest share of the mice model market

CRISPR is the most widely used technology in the mice model market and contributed to the largest share of the mice model market in 2020. Ease of design, high efficiency, and relatively lower cost have increased the demand for CRISPR-customized mice models.

By mice care product, cages segment accounted for the largest share of the mice model market

Based on mice care products, the mice model market has been segmented into cages, feed, bedding, and other products (gnotobiotic equipment, water systems, and accessories). The cages segment accounted for the largest share of the mice model market. This can be attributed to the availability of a wide range of cages designed for specific research needs and the higher cost of cages compared to other care products.

Asia Pacific: The fastest-growing region in the mice model market

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period. Several global pharmaceutical firms have entered the APAC market to tap the significant growth opportunities in emerging Asian countries and lower their production costs by shifting their drug discovery R&D operations and manufacturing to the region. A large number of qualified researchers and low-cost operations in APAC countries, such as India and China, are some of the major factors supporting this trend.

North America: The largest share of the drug discovery services market

North America, which includes the US and Canada, accounted for the largest share of the mice model market. The large share of the North America region can be attributed to the presence of major players operating in the mice model market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/17ab4p

Go here to see the original:
$1.9 Billion Mice Model Market by Mice Type, Technology, Application, Service, Care Products - Global Forecast to 2025 - ResearchAndMarkets.com -...

Read More...

Precision Medicine Market Research Report and Outlook by 2020 to 2025| Novartis International AG, F. Hoffmann-La Roche AG, AstraZeneca plc, Eli Lilly…

Friday, October 2nd, 2020

The study on the Global Precision Medicine Market Research delivers a profound comprehension of the market dynamics like drivers, the challenges, trends, and opportunities. The analysis further elaborates on the micro and macro-economic facets which can be predicted to shape the increase of the Precision Medicine Market through the forecast period.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Prominent Key Players Covered in the report:

Novartis International AG, F. Hoffmann-La Roche AG, AstraZeneca plc, Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Merck & Co. and others.

Click Here To Remain Ahead of Your Competitors, Request for Sample Report Of Precision Medicine Market @ https://www.adroitmarketresearch.com/contacts/request-sample/831

Report Focuses:

The report covers industry trends in the global market to help players develop effective long-term strategies. Business growth strategies adopted by developed and developing markets are highlighted. The report analyzes recent developments to understand the competitive market scenario and demand. Market trends and outlook coupled with factors driving and restraining the growth of the global Precision Medicine market. Detailed overview and segmentation of the global market, as well as its dynamics in the industry, are given.

To avoid getting left behind in an intensive competitive Global Precision Medicine Market, global companies need a new approach to ensure they create value in this environment. Amid increasing activities of M&A and growing activist-investor activity, Precision Medicine companies must strengthen their capabilities to maintain their market shares in the Precision Medicine industry.

Analytical Insights Contained from the Precision Medicine Market Report:

* Estimated earnings Rise of the Precision Medicine Market marketplace throughout the prediction phase* Facets anticipated to Help the Rise of the Precision Medicine marketplace* The expansion potential of this Precision Medicine Market marketplace in a Variety of areas* Consumption, pricing arrangement, and adoption routine of this Precision Medicine Market* Company profiles of top players at the Precision Medicine Market marketplace

The regional analysis covers:

* North America (*If you have any special requirements, please let us know and we will offer you the report as you want.)

Get Complete Details with TOC For Free @ https://www.adroitmarketresearch.com/industry-reports/precision-medicine-market

Global Precision Medicine Market is segmented based by type, application and region.

Based on Type, the Market has been segmented into:

NA

Based on application, the Market has been segmented into:

by Application (Oncology, Central Nervous System, Cardiology, Infectious disease and Others)

Table of Contents:

1. Executive Summary2. Assumptions and Acronyms Used3. Research Methodology4. Market Overview5. Global Market Analysis and Forecast, by Types6. Global Market Analysis and Forecast, by Applications7. Global Market Analysis and Forecast, by Regions8. North America Market Analysis and Forecast9. Latin America Market Analysis and Forecast10. Europe Market Analysis and Forecast11. Asia Pacific Market Analysis and Forecast12. Middle East & Africa Market Analysis and Forecast13. Competition Landscape

In conclusion, the Precision Medicine Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

Important Key Questions Answered:

* How will the global Precision Medicine Market advance in the coming years?* What are the main strategies adopted in the global market?* What is the nature of competition in the global Precision Medicine Market?* What are the opportunities and challenges for global market created by the outbreak of the Covid-19?* Which region may hit the highest market share in the coming era?Reasons To Pick AMR:* Powerful and prompt Customer Care* A methodical and systematic marketplace study procedure* Un-biased insights and marketplace decisions* Our insights have enabled the Development of over 500 customers* Reports made accessible as Our clients needs

Customization of the Report:

Adroit Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.Thanks for reading this article you can also get individual chapter wise section or region wise report version like North America, Europe, MEA or Asia Pacific.

Looking for provoking fruitful enterprise relationships with you!

Inquire for further detailed information of Global Precision Medicine Market Report @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/831

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Here is the original post:
Precision Medicine Market Research Report and Outlook by 2020 to 2025| Novartis International AG, F. Hoffmann-La Roche AG, AstraZeneca plc, Eli Lilly...

Read More...

USA Equities Corp. (USAQ), Announces its Application to Up-list to the OTCQB – GlobeNewswire

Friday, October 2nd, 2020

West Palm Beach, FL, Sept. 30, 2020 (GLOBE NEWSWIRE) -- USA Equities Corp. (OTC Link: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine, is proud to announce that it has begun the application process for an up-list of its common stock to the OTCQB Venture Marketplace. Unlike the OTC PINK, the OTCQB is recognized by the Securities and Exchange Commission (SEC) as an established public market and provides current public information to investors that need to analyze, value, and trade securities.

Because the OTCQB increases transparency, reporting standards, management certification and compliance requirements, this can result in greater liquidity and awareness for companies that meet the OTCQB tier standard.

"It has been an exciting past few months for USAQ as our wholly owned subsidiary Medical Practice Income introduced its unique software as a medical device platform to over 200 practicing physicians. The real life field experience with 200 plus physicians will form the basis from which we can verify all of the platforms features as we move towards a full scale launch of our software as a medical device. This strategic move creates the perfect time to move the Company to the next level," stated USA Equities Corp President & CEO Troy Grogan.

It's widely accepted that moving off of the 'pinks' to trading on the OTCQB can contribute to greater trading liquidity, a broader awareness and acceptance of the Company by the broker dealer and institutional investor community. This broader acceptance and added liquidity should result in the expansion of our shareholder base while adding to shareholder value.

"Our overall focus is on enhancing the diagnostic and patient monitoring capability of physicians while building a solid and profitable virtual care, digital medicine and remote patient monitoring business that will deliver meaningful economic returns to our shareholders. We believe this up listing, with its many benefits, will serve as a stepping stone to a future up listing on the NASDAQ or NYSE as we continue on our exciting growth curve," continued Mr. Grogan.

For more information about Medical Practice Income, or to become a participating physician, please visit https://www.medicalpracticeincome.com/opportunities.

About USA Equities Corp (OTC Link: USAQ)

On December 20, 2019 USA Equities Corp entered into and consummated a share exchange with the former stockholders of Medical Practice Income, Inc. (MPI), a Florida corporation. As a result of the Share Exchange, MPI became our wholly-owned-subsidiary. We are focused on value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. The Companys intellectual properties, products and information service portfolio is directed towards prevention, early detection, management and reversal of cardio-metabolic and other chronic diseases. Our principle objectives are to develop proprietary software tools, devices, and approaches, providing more granular, timely, and specific clinical decision-making information for practicing physicians and other health care providers to address todays obese, diabetic and cardiovascular disease population and is located in West Palm Beach, Florida. For more information, visit http://www.MedicalPracticeIncome.com/discover.

Forward-Looking Statements

This press release contains forward-looking statements which are identified by words such as may, could, believes, estimates, targets, expects, or intends and other similar words that involve risks and uncertainties. These statements have not been based solely on historical facts but on USA Equities Corp current expectations about future events and results. You should consider that as such statements relate to future matters, they are subject to various inherent risks, uncertainties and assumptions that could cause actual results or events to differ materially from expectations described in the forward-looking statement. Various important factors could cause actual results or events to differ materially from the forward-looking statements that USA Equities Corp makes, including, but not limited to, the risk that software development and studies may be delayed and may not have satisfactory outcomes, the risk that costs required to continue our Software as a Service (SaaS) or to expand our operations will be higher than anticipated and other risks described in the Risk Factors section of our Annual Report on Form 10-K filed by USA Equities Corp with the SEC on February 21, 2020. Except where required by law, USA Equities Corp. has no intention to update or revise forward looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation. None of USA Equities Corp Directors, Consultants, or any other person named with their consent in this presentation can assure you that any forward-looking statement or result expressed or implied by any forward-looking statement will be achieved.

Follow this link:
USA Equities Corp. (USAQ), Announces its Application to Up-list to the OTCQB - GlobeNewswire

Read More...

Aclipse Therapeutics Awarded AUD 1 Million Grant from FightMND – BioSpace

Friday, October 2nd, 2020

Sept. 29, 2020 11:00 UTC

RADNOR, Pa.--(BUSINESS WIRE)-- Aclipse Therapeutics, a private Pennsylvania biopharmaceutical company, was awarded an AUD 1 million (approximately US $720,000) drug development research grant from FightMND, the largest independent funder of ALS research in Australia. The grant will support the translational development of M102, a drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease. M102 showed promise to stop and reverse ALS disease progression, as evidenced by data in preclinical models. Currently, there is no cure for ALS and no effective treatments to halt or reverse the progression of this devastating disease.

We are very excited for ALS/MND patients, as FightMND is supporting our effort to advance this important therapy, which looks so promising in preclinical models, into clinical trials for our patients, said Professor Dame Pamela Shaw MD, a primary contributor to M102s development program. Professor Shaw is Professor of Neurology and the Director of the Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield (UK). Professor Shaw and her SITraN colleagues Dr. Richard Mead and Dr. Laura Ferraiuolo have led the key ALS/MND biology research and drug discovery of M102, as a fruition of their commitment and dedication to push the frontiers of science in ALS/MND for the benefit of patients over the last 20 years.

The FightMND grant will progress M102 into first-in-human trials. M102 is a disease-modifying drug candidate for ALS that activates NRF2 (nuclear factor erythroid 2-related factor 2) and HSF1 (Heat shock factor 1) signaling pathways, recently understood and important disease pathways in ALS. Aclipse is taking a multiple biological pathway, multiple disease mechanism approach to ALS. M102 is expected to be mechanistically superior to currently available drugs and may lead to significant slowing and reversal of disease progression in both familial and sporadic ALS. The FightMND grant will also support the development of patient stratification biomarkers that will be applied in the M102 clinical studies, and potentially enable a personalized medicine approach which is capable of identifying M102 responders vs. non-responders in the ALS patient population, and thus enriching M102s clinical trial patient population.

FightMND is excited about the prospects of this potential treatment. M102 has shown promise as an effective new treatment for ALS/MND patients, said Dr Bec Sheean, PhD, Research Director at FightMND. We are delighted to be supporting the development of M102, which has the potential to be a disease-modifying drug that improves on current standard-of-cares that only minimally delay disease progression for most MND patients.

We are honored by the support from FightMND which shares our vision for a novel and broad multi-disease pathomechanism approach to treating ALS patients, said Raymond K. Houck, CEO of Aclipse Therapeutics. He continued, The FightMND award also confirms M102s success to date and validates M102s potential for a precision medicine approach for the treatment of ALS.

About ALS/MND

Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease, is a progressive neurodegenerative disease that affects motor neurons (nerve cells) in the brain and the spinal cord. Eventually, people with ALS/MND lose the ability to initiate and control muscle movement, which often leads to total paralysis and death within two to five years of diagnosis. There is no cure and limited life-prolonging treatments for the disease. Based on Australian population studies, more than 2,000 people are currently fighting ALS/MND in Australia: 60% male and 40% female. In 2013, ALS/MND accounted for 1 in 200 deaths in Australia. Based on U.S. population studies, approximately 5,600 people in the U.S. are diagnosed with ALS/MND each year and as many as 20,000 Americans have the disease at any given time. ALS/MND patients exist on all populated continents.

About FightMND

Founded in 2014, FightMND was established in Australia with the purpose of finding effective treatments and ultimately a cure for motor neuron disease (MND), also referred to as ALS or Lou Gehrig's Disease. FightMND, with its vision of a world without MND, is the largest independent funder of MND research in Australia. What FightMND has done since 2014, is be the voice and the guiding star for Australians who want to fight "The Beast". Integral to this vision is the determination to help facilitate the translation of the growing body of new knowledge about the disease into a cure for MND patients in Australia and abroad. For more information about FightMND, visit the website at https://fightmnd.org.au.

About Aclipse Therapeutics

Aclipse Therapeutics develops novel and highly differentiated drugs to treat orphan diseases with significant unmet medical needs. Our lead drug candidate, M102, is in development for the treatment of ALS with upside uses in Huntington's disease, Friedreichs ataxia, and Parkinson's disease. M102 targets multiple disease pathomechanisms and enables a precision medicine approach for the identification of patients who are most likely to benefit from the drug. Aclipse has a very experienced orphan drug management team and a clinical advisory board of the top ALS physicians in the world. For more information about Aclipse, visit the website at https://aclipsetherapeutics.com or email info@aclipsetherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005077/en/

Read the original here:
Aclipse Therapeutics Awarded AUD 1 Million Grant from FightMND - BioSpace

Read More...

Endpoint Health and Vanderbilt University Medical Center to Create Worlds First Precision Medicine Trial Network Focused on Critical Illness – IT…

Friday, October 2nd, 2020

Late-stage interventional trials will evaluate personalized approaches to existing care and novel targeted therapies

PALO ALTO, Calif.(BUSINESS WIRE)Endpoint Health, the first targeted therapeutics company focused on integrated solutions for critical illnesses, today announced a new strategic partnership with Vanderbilt University Medical Center (VUMC) to create the first precision medicine clinical trial network focused on late-stage clinical trials in critical illness. The network will combine leading critical illness researchers, trialists and premier medical centers from across the country to create a sustained system for conducting phase II and III interventional trials intended to validate precision medicine technologies, therapies, and deployable patient-centric care approaches. It will prioritize trials investigating promising precision-driven interventions to prevent or treat critical illnesses such as sepsis and acute respiratory distress syndrome (ARDS), which are the most expensive conditions to treat in the hospital setting and are associated with half of U.S. hospital mortality.

Endpoint Health envisions a future where clinicians are empowered with an array of targeted therapies and personalized approaches to improve the outcomes of their sickest patients, said Jason Springs, co-founder and CEO of Endpoint Health. Our partnership with VUMC will establish a foundational piece of the ecosystem necessary to make this vision real for the critical care community.

VUMC will serve as the trial network coordinating center with Endpoint Health providing the underlying technology that leverages digital and molecular patient data to predict likely therapeutic response. The goal of the network is to conduct an ongoing series of trials that study multiple precision-driven interventions to treat or prevent critical illness. Endpoints technology is already being piloted in a phase II randomized controlled trial at VUMC, which started enrolling patients this month. Endpoint will also sponsor the first precision interventional trial, which will evaluate one of the companys investigational products.

Precision medicine in critical care has long been a goal that healthcare has struggled to attain due to the complex and fast-moving nature of critical illnesses, said Dr. Todd Rice, Director of the Medical Intensive Care Unit at VUMC. Our partnership with Endpoint Health will help turn that vision into a reality. Together, we are building the infrastructure needed to run efficient and effective precision clinical trials that use advanced technologies to guide patient enrollment and treatment selection that ultimately improve patient outcomes.

COVID-19 has put a spotlight on the need for better, more personalized care that addresses critically ill patients in both the ED and ICU, said Dr. Wesley Self, Vice Chair of Research in the Department of Emergency Medicine at VUMC. Our ability to validate new treatments in a manner that can be translated into actual clinical practice quickly and effectively is an essential step to bringing life-saving targeted therapies to some of the sickest patients. This is an exciting development for the medical community, and ultimately patients, as it will facilitate significant new research and therapy discovery opportunities.

About Endpoint Health

Endpoint Health combines therapeutics, companion diagnostics, and artificial intelligence (AI) into an integrated platform designed to improve outcomes of patients with critical illnesses like sepsis, acute respiratory distress syndrome (ARDS), and COVID-19. The company is based in Palo Alto, Calif., with offices in Detroit and Chicago, and is backed by top-tier investors including Mayfield, Y Combinator, AME Cloud Ventures, and Wireframe Ventures. For more information visit http://www.endpoint.health.

Contacts

Amanda Cox

Health+Commerce

(925) 708-5665

amanda@healthandcommerce.com

See more here:
Endpoint Health and Vanderbilt University Medical Center to Create Worlds First Precision Medicine Trial Network Focused on Critical Illness - IT...

Read More...

Dr. Chu on the Role of Pembrolizumab in dMMR/MSI-H mCRC – OncLive

Friday, October 2nd, 2020

Edward Chu, MD, MMS, discusses the role of pembrolizumab in patients with mismatch repair deficient or microsatellite instabilityhigh metastatic colorectal cancer.

Edward Chu, MD, MMS, director and professor of medicine and molecular pharmacology at Albert Einstein Cancer Center, and vice president for cancer medicine at Montefiore Medicine, discusses the role of pembrolizumab (Keytruda) in patients with mismatch repair deficient (dMMR) or microsatellite instabilityhigh (MSI-H) metastatic colorectal cancer (mCRC).

The phase 3 MK-3475-177/KEYNOTE-177 trial demonstrated a significantly improved overall response rate, duration of response, and progression-free survival with pembrolizumab versus investigators choice of standard-of-care chemotherapy, says Chu. Moreover, pembrolizumab demonstrated a favorable safety profile compared with chemotherapy.

On June 29, 2020, the FDA approved pembrolizumab as a first-line therapy for patients with unresectable dMMR or MSI-H mCRC based on results from the KEYNOTE-177 study. The regimen should now be considered a standard of care for this patient population, Chu adds.

Notably, patients with dMMR or MSI-H mCRC account for about 5% of the overall mCRC population.Although the subset is small, the activity of pembrolizumab in this space confirms the need for precision medicine and personalized therapeutic approaches for patients with CRC, concludes Chu.

Here is the original post:
Dr. Chu on the Role of Pembrolizumab in dMMR/MSI-H mCRC - OncLive

Read More...

Progenity Supports the Preeclampsia Foundation Call to Action to Accelerate Development and Adoption of Biomarker Tests for Preeclampsia -…

Friday, October 2nd, 2020

SAN DIEGO, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced support for the Preeclampsia Foundations recent call to action advocating for accelerating the development and clinical adoption of biomarker tests for the diagnosis of preeclampsia, a life-threatening hypertensive disorder of pregnancy. The foundation issued its call to action urging the life science community and policy makers to accelerate the development and adoption of biomarker-based testing for preeclampsia.

We support the Preeclampsia Foundation both in their mission and in their call for accurate testing for preeclampsia, said Harry Stylli, PhD, CEO, chairman of the board, and co-founder of Progenity. The need is urgent because, while preeclampsia rates are continuing to rise, healthcare providers today are still evaluating symptoms and risk using technology from the late 1800s. We are demonstrating our commitment to this cause by investing in the development of a biomarker-based test that is currently in an advanced stage of development. This test, which is potentially the first of its kind, could bring more personalized care to aid in the diagnosis and treatment of preeclampsia.

Preeclampsia occurs in 5 to 8% of pregnancies and is a leading cause of preterm birth and maternal and infant death. A progressive condition that can occur during the third trimester of pregnancy, preeclampsia is typically characterized by elevated blood pressure, edema (swelling in hands or face), and protein in the urine. The cause of preeclampsia is not fully understood and involves multiple pathophysiologic pathways. It is estimated that over 700,000 pregnant women in the United States experience signs or symptoms that could be attributed to preeclampsia each year, but symptoms can be difficult to differentiate from those of other hypertensive disorders of pregnancy. Healthcare providers in the United States are primarily equipped with non-specific tools developed over 100 years ago to diagnose this potentially deadly condition.

Progenity is currently developing a novel biomarker blood test designed to rule out preeclampsia in symptomatic women during the third trimester. This objective risk assessment tool is designed to help healthcare providers differentiate between preeclampsia and other, lower-risk hypertensive disorders. By identifying patients who are not at risk for developing preeclampsia, the test could enable healthcare providers to better guide patient care and maintain pregnancies to term when possible. This will potentially lead to fewer unnecessary hospitalizations and preterm deliveries in this patient population, while providing added reassurance for patients.

To lend support to the Preeclampsia Foundations call to action, clinicians, researchers and patients are encouraged to sign their petition for change.

About Progenity

Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenitys vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For additional information about Progenity, please visit the companys website atwww.progenity.com.

Safe Harbor Statement or Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the development of our preeclampsia rule-out test are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as may, might, will, objective, intend, should, could, can, would, expect, believe, design, estimate, predict, potential, plan or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to develop and commercialize our preeclampsia rule-out test and those risks described in Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations in Progenitys Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, filed with the SEC on August 14, 2020, and other subsequent documents we file with the SEC.

Progenity expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:Robert UhlManaging Director, Westwicke ICRir@progenity.com (619) 228-5886

Media Contact:Kate Blom-LoweryCG Lifekblomlowery@cglife.com (619)743-7294

More:
Progenity Supports the Preeclampsia Foundation Call to Action to Accelerate Development and Adoption of Biomarker Tests for Preeclampsia -...

Read More...

Monoclonal Antibodies, ADCs, and CAR T Cells Invigorate the Myeloma Paradigm – OncLive

Friday, October 2nd, 2020

BCMA-directed therapies, such as bispecific monoclonal antibodies, CAR T-cell therapy, and antibody-drug conjugates (ADCs), are in the midst of transforming the treatment paradigm of relapsed/refractory multiple myeloma to get closer to a cure for patients, said David H. Vesole, MD, PhD.

We keep striving for a cure. Right now, we have the option to make this a chronic disease in the same way high blood pressure or diabetes [are chronic diseases]. We didnt have that option when I started. We can control a patients disease for an unbelievably extended period of time. Even if we dont cure patients, we can make it a chronic disease, said Vesole. This is exciting for patients and their families. most of these therapies can be given with the prolongation of life, without negatively impacting QOL a great deal.

In an interview with OncLive, Vesole, director of the Myeloma Program at MedStar Georgetown University Hospital, professor of medicine at Georgetown University, co-director of the Myeloma Division and director of Myeloma Research at John Theurer Cancer Center at Hackensack University Medical Center, discussed the evolution of multiple myeloma treatment, and explained how other BCMA-therapies are poised to impact clinical practice.

OncLive: What makes BCMA a logical target in multiple myeloma?

Vesole: All patients with multiple myeloma are BCMA positive. BCMA stands for B-cell maturation agent, and all myeloma cells have some expression of BCMA on their cell surface. The extent of BCMA positivity may be higher or lower for individual patients, but because they are all positive, BCMA serves as a very efficient target for BCMA-directed therapies.

How has the treatment of multiple myeloma evolved?

Ive been caring for patients with multiple myeloma for over 30 years, and treatments have evolved tremendously over the years. Back in the day, all of our drugs were chemotherapies, which have a lot of bystander effects and can cause nausea and vomiting.

It wasnt until proteasome inhibitors (PIs), which were enzyme-specific pathway inhibitors that were first approved in 2003, that we started [using] targeted therapies for specific pathways and cells. These [agents] had significantly fewer bystander effects on normal cells. Therefore, since 2003, [multiple drugs have been] approved for the treatment of myeloma. Most of the [newer treatments] are more sensitive and specific to myeloma cells with much less bystander effect. They are tolerated better and their efficacy is better than conventional chemotherapy.

Over the course of the past few years, we found that giving combination therapies with multiple mechanisms of action results in superior activity, such that triplets appear to be the standard of care for newly diagnosed patients. [These triplets] are based on different categories of drugs such as PIs, immunomodulatory drugs (IMiDs), and corticosteroids. Many trials have looked at triplets versus doublets, and essentially all of them show that triplets are superior to doublets in the frontline and relapsed/refractory settings.

Currently, triplet therapy seems to be the standard of care, but what is evolving is whether we should give quadruplet regimens with monoclonal antibodies in addition to those same 3 classes of drugs I mentioned. Emerging data indicate that [quadruplets] are even more efficacious without a significant increase in toxicity. Although they are not currently the standard of care, I anticipate within the next 5 years that they will become the standard of care potentially up front, as well as in the relapsed/refractory settings for patients with multiple myeloma.

It is exciting to know that we have these monoclonal antibodies, which target specific surface components of myeloma cells. They [cause] very few bystander effects on other cells in the body. Although [these agents] are not completely devoid of other toxicities, they focus predominantly on myeloma cells.

[Historically], we would see, at most, a 20% likelihood of achieving a complete remission (CR). Now, we are approaching potentially achieving CRs in 80% or more of patients depending on the regimen that we utilize. Overall survival (OS) [rates] have improved as well [compared with] when I first started more than 30 years ago. Currently, patients with stage I disease have a life expectancy that exceeds 10 to 15 years versus 2.5 years [when I first started].

What challenges remain with regard to treatment in multiple myeloma?

The biggest hurdle that we still have in multiple myeloma is [treating] patients with high-risk disease based on [their] cytogenetics and staging. Weve certainly made major headway, but their OS remains in the 4- to 6-year range, which is much lower than what we see with those patients who do not have adverse cytogenetic features.

Belantamab mafodotin-blmf (Blenrep) received regulatory approval in August 2020. How does this agent compare with others in the space?

The first BCMA-directed therapy that has been FDA approved is belantamab mafodotin. It is an ADC where the antibody is directed against BCMA and is conjugated to a chemotherapy drug. Biologically, the monoclonal antibody attaches to the myeloma cell, which is endocytosed into the cell. Then, lysozymes break down the link between the chemotherapy drug and the antibody, which allows the chemotherapy drug to kill the cell [from within]. Other diseases have ADCs as well, but [belantamab mafodotin] is the first approved in multiple myeloma.

For patients who respond [to belantamab mafodotin], the duration of response exceeds 11 months. This is quite impressive for a group of patients whose lifespan would be shorter than patients who have not received 4 prior lines of therapy. This opens up a wide avenue of patients with multiple myeloma who may have exhausted all other potential treatments.

The drug does not [elicit] an overly robust response rate as a single agent. [The rates are] about 30% to 35% depending on which DREAMM study you look at. As a single agent, belantamab mafodotin is currently approved for patients who have been heavily pretreated with 4 or more prior lines of therapywhich is a lot of chemotherapy.

Could you describe the unique safety profile of belantamab mafodotin?

Yes, there are some bystander effects with [belantamab mafodotin]. From a hematologic standpoint, it can lower white [blood cell] counts and platelet counts, but that is usually not a major consequence.

However, for reasons that we do not know, [belantamab mafodotin] can cause problems with the eye, [namely] keratopathy. In the vast majority of patients, this is very minor and presents as blurred vision or dry, scratchy eyes. Although this occurs in about 80% of patients treated with the drug, severe reactions occur in about 10% of patients. To the best of my knowledge, most of these abnormalities are completely reversible with time. The time sequence of the reversibility depends on how severe [the toxicity] is. There is a grading system from 1 to 4 with regard to how involved the ophthalmologic abnormalities are.

Before each dose of [belantamab mafodotin], which is administered every 3 weeks, patients have to be seen by an ophthalmologist or optometrist to be cleared before receiving the next dose of therapy. If a patient meets certain grades of severity, the drug is either dose reduced or held.

Although this is the first approved [BCMA-directed] drug, there are a lot of other therapies directed against BCMA that have different toxicity profiles than belantamab mafodotin.

Selinexor (Xpovio) is another drug that was recently approved for patients who have had 4 prior lines of therapy. Selinexor is an [oral] pill given once or twice a week, depending on the schedule. It is not a BCMA-directed agent. Instead, selinexor is directed against a specific mechanism in the nucleus of the myeloma cells [called XPO1]. Selinexor has a completely different toxicity profile; gastrointestinal toxicities are mainly seen with this agent.

The FDA approval of belantamab mafodotin was based on data from the DREAMM-2 trial. How has the DREAMM series evolved since the approval?

The DREAMM-1 study essentially [evaluated whether] belantamab mafodotin had any activity [in patients with relapsed/refractory multiple myeloma]. DREAMM-2 is the phase 2 trial that led to the FDA approval for the drug. DREAMM-3 through DREAMM-16 [are trials] that are evaluating a variety of other agents to be added to belantamab mafodotin. Additionally, DREAMM-12 and DREAMM-13 are evaluating belantamab mafodotin in patients with renal failure and liver abnormalities, [respectively].

Essentially, [the trials] are taking all the known drugs that we currently use to treat patients with multiple myeloma and adding them to belantamab mafodotin in some form. The DREAMM series is an ongoing effort to improve the outcome of single-agent belantamab mafodotin. DREAMM-6 was presented at [the 2020 ASCO Virtual Scientific Program] in June, showing response rates north of 30% with the addition of bortezomib (Velcade), [which is] far superior [than what weve seen with belantamab mafodotin alone]. When we combine belantamab mafodotin with other active agents with different mechanisms of action, we can see superior response rates and remission durations.

How do you approach sequencing in your own practice? Where does belantamab mafodotin fit into the paradigm?

Although quadruplets are quite effective up front, they are not FDA approved at this point in time. We are not sure if they will be covered by third-party carriers. Therefore, we generally use triplet regimens for initial therapy.

Our group is heavily biased toward stem cell transplants, which is considered standard of care throughout the world. For patients who have multiple myeloma and adequate physiologic organ function, and agree to [undergo] transplant, transplant is considered standard. We would give a triplet regimen, followed by transplant. Our group is a bit unique because we are not particularly in favor of maintenance therapy. On average, patients stay in remission for 2.5 to 5 years. Then we come back with salvage therapy, usually with triplet regimens, of which there are a number approved by the FDA for patients who have had 1 to 3 prior lines of therapy.

Belantamab mafodotin was approved in kind of a niche sense in that it is approved for patients who had 4 prior lines of therapy. [The FDA] doesnt specify lines of therapies, so it is an interpretation of what that means. The agent was only tested in patients who had 4 or more lines of therapy. It is a little bit confusing because, in theory, we could use [belantamab mafodotin] in the second- or third-line settings.

There will likely be a lot of competing options for BCMA-directed therapy. CAR T-cell therapy is likely going to be approved sometime in the first quarter of 2021. Two companies are neck-and-neck with the FDA submission for CAR T-cell therapy approval. [Both] are BCMA-directed therapies.

Bispecific antibodies are a little bit further away from receiving regulatory approval, but are also BCMA-directed therapies.

There will certainly be a lot of competition for belantamab mafodotin in this niche [setting of patients who received at least 4 prior therapies]. These other agents have different toxicities profiles and different response rates. Similar to the DREAMM studies, these agents are being combined with many of the standard therapies that we currently use. We are going to have a whole list of additional options with these BCMA-directed therapies in the very near future.

Where would you like to see future research efforts focused?

Right now, belantamab mafodotin is being given as a single agent. We are not going to control multiple myeloma with single agents. We need combination therapies that have different mechanisms of action. That is ultimately going to be the goal of treatment.

The future is going to have personalized medicine. There is a trial by the Multiple Myeloma Research Consortium that is using standard therapies and then doing next-generation sequencing to find out if there are specific gene mutations for which specific drugs can be directed toward. The investigators are giving individual drugs, based on the patients DNA sequencing, that will attack specific abnormalities.

Ultimately, this is what is going to happen. We are going to be individualizing precision medicine and treating patients specific DNA abnormalities in their myeloma cells.

Yes, we could have a BCMA-directed target, but if we add that with a targeted agent against some specific enzyme deficiency or genetic abnormality, it [will be a valuable] addition to these other mechanisms. I imagine that in the future, patients are going to get 4 or 5 different drugs, some specific to enzyme pathways, others specific to their individual DNA sequencing. That is, in addition to targets that are widely expressed on the myeloma cells themselves such as BCMA.

How do you see CAR T-cell therapy impacting the landscape of multiple myeloma?

CAR T-cell therapy is an exciting area now. CAR T cells are patients own lymphocytes that are genetically modified to improve their activity in targeting their own myeloma cells. Unlike belantamab mafodotin, which, as we mentioned, needs to be combined with other agents to improve efficacy, CAR T-cell therapy alone has a response rate of 75% to 100%.

Further, CAR T-cell therapy is [a] one-and-done [approach]. Patients get CAR T cells on day 1 and they may not need therapy for 1 or 2 years, perhaps longer. All the other BCMA-directed therapies require continuous and indefinite therapy until they no longer work. With CAR T cells, patients get their therapy, get their response, and may not require treatment for an extended period of time. Ultimately, this will result in superior quality of life (QOL) for those patients who are going to get continuous therapy.

The CAR T-cell technology continues to improve. There are probably over 30 different companies that are trying to [manufacture] CAR T cells in multiple myeloma. The vast majority of them are using BCMA as the target, but that is not the only target that is available.

Right now, CAR T cells are predominantly made using a patients own cells, which takes 2 to 4 weeks to generate, genetically modified, and engineered before being returned to the patient. In the future, there will also be what we call off-the-shelf CAR T cells that are made in a laboratory and can be given the day after ordering them. Studies evaluating these allogeneic

CAR T cells are just beginning, but they could save a lot of time. Some patients cannot generate good CAR T cells if they have been heavily pretreated or if they dont generate the number of cells needed for the infusion. Allogeneic CAR T-cell therapy opens [the option] up for those patients, as well as for the patients who need treatment sooner rather than later; some patients cannot wait 2 to 4 weeks for the cells to be generated.

To me, this is the most exciting area because it is a one-and-done [approach] versus continued therapy. CAR T-cell therapy can cause toxicities, but in contrast to lymphoma and leukemia, most of them are minor in multiple myeloma. [Moreover,] there is at most a 10-day window in which these abnormalities occur, after which patients are essentially home free for the duration of time the cells are effective.

Original post:
Monoclonal Antibodies, ADCs, and CAR T Cells Invigorate the Myeloma Paradigm - OncLive

Read More...

Personalized Medicine and Epigenomics Market (Covid-19 Updated) Opportunities And Analysis By Expansion, Size, Share, Trends, Manufacturer And…

Wednesday, September 16th, 2020

Personalized Medicine and Epigenomics Market has been growing exponentially over time and has shown great potential in the near future. The growth of Personalized Medicine and Epigenomics Market is expected to see an amazing uproar as the market becomes increasingly popular. The report focuses on the key growth contributors of the market to help the clients better understand the current scenario of the market all while considering the history as well as the forecast of the Personalized Medicine and Epigenomics Market. Essential growth factors have been discussed in the following report.

Top Companies covering This Report:- Emd Millipore, Epigenomics AG, Epigentex, Envivo Pharmaceuticals (Forum Pharmaceutricals), Gilead Sciences, Glaxosmithkline, Illumina Inc., Johnson & Johnson, Karus Therapeutics Limited, Laboratory Corp. Of America Holdings, LES Laboratoires Servier, Merck, Naturewise Biotech & Medicals Corp.

The report assesses the important factors and aspects that are crucial to the client to post good growth in revenue as well as business expansion. Some of these aspects are sales, revenue, market size, mergers and acquisitions, risks, demands, new trends and technologies and much more are taken into consideration to give a complete and detailed understanding of the market conditions. Coupled with your expertise this report can make you a big player in the Personalized Medicine and Epigenomics Market and can get you in the frontrunners of the Personalized Medicine and Epigenomics Market.

Get Sample PDF Brochure@https://www.reportsintellect.com/sample-request/1057775

Description:

This report has concise and apt data on the Personalized Medicine and Epigenomics market which is updated as the international markets change. The past few years the markets have changed drastically and its becoming harder to get a grasp of and hence our analysts here at Reports Intellect have prepared a detailed report while taking in consideration the market issues and their solution to give you the best information and leverage on your competition.

The given report emphasizes on the key aspects of the markets to ensure maximum profit and growth potential for clients. Our Comprehensive analysis of the market will help the clients to achieve this much more efficiently. The report is suited well for all kinds of approaches to ensure the ease without any interruptions caused to your preferred work approach.

Personalized Medicine and Epigenomics Market Type Coverage:

ReagentsKitsInstrumentsEnzymesServices

Personalized Medicine and Epigenomics Market Application Coverage:

OncologyNon-OncologyCancer Drug Technology

Market Segment by Regions and Nations included:

North America (United States, Canada, Mexico)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia)

South America (Brazil, Argentina, Colombia, etc.)

Europe, Middle East and Africa (Germany, France, UK, Russia and Italy, Saudi Arabia, UAE, Egypt, Nigeria, South Africa)

Discount PDF Brochure @https://www.reportsintellect.com/discount-request/1057775

Why us:

Reasons to buy:

About Us:

Reports Intellect is your one-stop solution for everything related to market research and market intelligence. We understand the importance of market intelligence and its need in todays competitive world.

Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you.So whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact Us:

sales@reportsintellect.comPhone No: + 1-706-996-2486US Address:225 Peachtree Street NE,Suite 400,`Atlanta, GA 30303

More:
Personalized Medicine and Epigenomics Market (Covid-19 Updated) Opportunities And Analysis By Expansion, Size, Share, Trends, Manufacturer And...

Read More...

Page 15«..10..14151617..2030..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick